{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:53:02Z","timestamp":1773978782446,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.102090","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T05:41:11Z","timestamp":1712468471000},"page":"102090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5486-2983","authenticated-orcid":false,"given":"Evangelia","family":"Vlachou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burles Johnson","family":"III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-6509","authenticated-orcid":false,"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nimgaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clgc.2024.102090_bib0001","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2024.102090_bib0002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102090_bib0003","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clgc.2024.102090_bib0004","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2021.12.062","article-title":"Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes","volume":"87","author":"Shao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102090_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102090_bib0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2022.12.009","article-title":"In patients with advanced urothelial carcinoma, immune checkpoint inhibition prior to enfortumab vedotin is associated with high-grade skin toxicity","volume":"83","author":"Molina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102090_bib0007","unstructured":"Birnbaum, B. et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. (2020)."},{"issue":"16","key":"10.1016\/j.clgc.2024.102090_bib0008","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","volume":"03","author":"Ma","year":"2020","journal-title":"medRxiv"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T06:26:30Z","timestamp":1717655190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000612"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102090","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102090"}}